Go to deals
Healthcare

EOS Imaging has raised US$51 million in its IPO on NYSE Euronext

Venture-backed medical device company EOS Imaging has raised US$51 million in its IPO on NYSE Euronext. Based on the opening trade price, the company is valued at approximately US$146 million. Investors include medical device-focused venture capital firm NBGI Ventures and Edmond de Rothschild Investment Partners, which has been the lead investor and the company’s largest shareholder since 2005.

EOS Imaging designs, develops and markets EOS, a medical imaging system revolutionizing the treatment chain of the main osteoarticular diseases (hips, knees, back) and related orthopedic surgery. Based on the work of Physics Nobel Prize Winner Georges Charpak, the EOS system is the first imaging solution capable of producing, in one step, a 2D and 3D image of the upright skeleton with a very low radiation dose. EOS 2D/3D images are produced in the patient’s natural functional position, raising the accuracy of diagnosis, surgery and osteoarticular pathological follow-up.

The success of the IPO confirms EOS Imaging’s outstanding technology pedigree, its sound commercial and clinical proposition and its potential for strong commercial growth on a global level.

Oaklins’ team in France was appointed by the shareholders of EOS Imaging to launch an initial public offering and proposed listing of the company’s shares on compartment C of the regulated market of NYSE Euronext.

Talk to the deal team

Thibaut de Monclin

Managing Partner
Paris, France
Oaklins France

Related deals

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more
Omer Engineering has completed an IPO
Real Estate

Omer Engineering has completed an IPO

Omer Engineering Ltd. has successfully launched its IPO on the Tel Aviv Stock Exchange, pricing shares as part of a plan to raise approximately US$94 million at an implied pre-money valuation of around US$313 million. The offering included both newly issued shares and a secondary sale by existing shareholders, who retained a significant majority stake post-IPO. This transaction underscores strong investor interest in scaling the company’s operations and enhancing its capital.

Learn more
Smart Capital has finalized a rights issue
Financial Services

Smart Capital has finalized a rights issue

Smart Capital S.p.A. has finalized a rights issue to continue executing its growth plan and increase its investment capacity. The fundraising supports the expansion of its investment portfolio and the strengthening of its positions in higher-quality investee companies with stronger growth prospects.

Learn more